AMRZ

Amrize Ltd

$38.80

-0.08% Oct 21 close

Basic Materials Compare Technicals

1M 3M 6M 1Y 2Y

AMRZSPY

+6.9%

+0.5%

-21.5%

-30.6%

YTD

-27.4%

-19.9%

Live chart

Loading live chart…

What they do

Amrize AG engages in the provision of various building solutions for infrastructure, commercial, and residential construction markets in North America and Canada. It operates through two segments, Building Materials and Building Envelope. The Building Materials segment offers cement and aggregates, as well as ready-mix concrete, asphalt, and other construction materials.

Basic Materials · Building Materials

For information only · Important disclosures

Grades vs sector

No sector grades for AMRZ yet. Grades rank S&P 1500 stocks within their sector and refresh after each daily data run, so a stock outside that index or newly covered has none.

Our models

Not held by any of our 5 live models right now.

Quality Growth

Outside this model's universe or screens

Momentum Top 15

Outside this model's universe or screens

Momentum Blend

Not in the current book

New Highs Growth

Outside this model's universe or screens

Coteau Long Book

Not in the current book

News

More news

Earnings Preview: Amrize Ltd (AMRZ) Q3 Earnings Expected to Decline

Zacks · Oct 21

Amrize (AMRZ) Benefits from Regional Scale, Tight Supply Dynamics, and Pricing Power

Insider Monkey · Oct 15

Amrize Announces Date for Third Quarter 2026 Financial Results

Business Wire · Oct 14

RBC Cuts Price Target on Amrize to $32 From $48, Keeps Underperform Rating

MT Newswires · Oct 09

Asurion Names Baris Oran Chief Financial Officer

PR Newswire · Oct 05

Key stats

Market value$21.2B

P/E (last 12 months)17.7

P/E (next 12 months, estimated)13.5

52-week range$35.78 – $65.94

Revenue growth (latest quarter vs a year ago)+8.6%

Dividend yieldNo dividend

Analyst consensusBuy (19)

Average analyst price target$47.15 (+22%)

Valuation and fundamentals

Valuation & fundamentals

Bottom line

Leans undervalued

Model read-out from the numbers below, not advice. Score +1 (DCF counts double).

•DCF (base case)above the price by 7%

•Piotroski F-score4/9

•Altman Z1.9 (grey)

•Net debt / EBITDA2.0x

▲Analyst target+22% (19 analysts)

Discounted cash flow

Bear

$23

-41%

growth 4% · disc. 10.2% · term. 2.0%

Base

$42

+7%

growth 9% · disc. 9.2% · term. 2.5%

Bull

$68

+74%

growth 12% · disc. 8.2% · term. 3.0%

A DCF starts from trailing free cash flow, so it can overstate value if the last 12 months were unusually strong (or weak). Use the bear case or edit the starting cash flow if so.

Reverse DCFfor context, not a signal

Today's price assumes free cash flow grows about 6% a year for 10 years.

Implied

+6%/yr

FCF, last 3 yrs

n/a

FCF, last 5 yrs

n/a

Revenue, last 3 yrs

n/a

Revenue, last 5 yrs

n/a

Same inputs as the DCF above: trailing free cash flow 1.3B, 9.2% discount rate, 2.5% growth after year 10, net debt and today's share count. Actual growth rates are compound annual rates from SEC annual filings through FY2025; "n/a" means too little history or a negative starting year.

Edit assumptions · recalculates instantly

Your value per share–

Free cash flow = operating cash flow − capital spending, trailing 12 months (TTM to 2026-06-30). Growth default: average of 3-year revenue CAGR and latest revenue growth, capped at 30%. Years 6–10 fade linearly to terminal growth. Discount rate = 4.25% risk-free assumption + beta 1.00 (n/a) × 5% equity premium, kept within 7–13%. Bear: lower growth, +1 pt discount, 2% terminal. Bull: higher growth, −1 pt, 3%.

Multiples vs sector

Forward EPS $2.86 vs trailing $2.19 (+31% expected growth). Forward P/E uses analysts' next-12-month estimate.

Backlog (remaining performance obligations)

RPO

$445.0M

as of 2025-12-31

vs a year ago

–

YoY

× TTM revenue

0.04×

coverage

25-06

25-09

25-12

Contracted revenue not yet recognized, from SEC filings (XBRL tag RevenueRemainingPerformanceObligation).

Quality & financial health

Gross margin

25.1%

Operating margin

15.5%

FCF margin

10.8%

Net margin

10.1%

Return on equity

9.6%

Return on invested capital

8.2%

Net debt / EBITDA

2.0×

Current ratio

1.1×

Interest cover

5.2×

Cash conversion (OCF/NI)

1.8×

Piotroski F-score 4/9 · last two fiscal years

✓ Positive net income✓ Positive operating cash flow✗ Return on assets improved✓ Cash flow above net income✗ Long-term debt / assets fell✗ Current ratio improved✓ No share dilution✗ Gross margin improved✗ Asset turnover improved

Altman Z-score 1.9 (grey zone; above 3.0 = safe, below 1.8 = distress). Not meaningful for banks and insurers.

Analysts

Mean target

$47

+22%

Analysts

Buy

Range

$32–$64

low – high

● price · ◆ mean target

Annual history

FY	Revenue	Net income	Free cash flow
2025	$11.8B	$1.2B	$1.4B
2024	$11.7B	$1.3B	$1.6B
2023	$11.7B	$956.0M	$1.4B

From the company's 10-K filings via SEC XBRL. 3-year revenue CAGR –.

Earnings

Next report: 2026-10-28 · after close · EPS est 0.88

EstimateActual (beat)Actual (miss)

Report	EPS est	Actual	Surprise
2026-08-06	0.94	0.86	-8.8%
2026-04-29	-0.15	-0.21	-39.8%
2026-02-17	0.64	0.54	-16.2%
2025-10-28	1.03	1.13	+10.2%
2025-08-06	1.13	0.78	-31.0%

Quarterly revenue

Quarter	Revenue	YoY
2026-06-30	$3.5B	+8.6%
2026-03-31	$2.2B	–
2025-12-31	$2.8B	–
2025-09-30	$3.7B	–
2025-06-30	$3.2B	–

Rating changes

Reiterated

2026-10-19 · Barclays reiterated Equal-Weight on AMRZ

Reiterated

2026-10-13 · JP Morgan reiterated Neutral on AMRZ

Initiated

2026-10-12 · Longbow Research started covering AMRZ at Buy

Reiterated

2026-10-09 · RBC Capital reiterated Underperform on AMRZ

Reiterated

2026-10-05 · Wells Fargo reiterated Equal-Weight on AMRZ

Reiterated

2026-10-05 · Truist Securities reiterated Hold on AMRZ

Third-party analyst actions, not Coteau's views. All rating changes